Regulatory approval
Published by the Health Service Executive. Approved
As monotherapy for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated with at least one prior line of systemic therapy.
This is written in the approval document.
Reimbursement
CDS
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | IDH1 p.R132C | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132G | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132H | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132L | Cholangiocarcinoma | Ivosidenib | |
| HSE (1) | IDH1 p.R132S | Cholangiocarcinoma | Ivosidenib |